Meta-analysis investigates response rates of BTK inhibitors in B cell lymphomas, suggesting effectiveness of zanubrutinib.
Consistent with the results of existing head-to-head trials, zanubrutinib demonstrated either numerically or statistically significant improved CR and ORR compared to acalabrutinib and ibrutinib across B cell lymphomas. Similar trends were observed within each indication. These findings suggest that zanubrutinib is the most effective BTKi treatment option for patients across B cell lymphomas.
No takes yet. Share an insight, caveat, or question.
Zinzani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: